PURPOSE: To assess the feasibility of hybrid imaging of the heart with fluorine 18 fluorodeoxyglucose (FDG) on an integrated 3-T positron emission tomography (PET)/magnetic resonance (MR) imaging system. MATERIALS AND METHODS: The present study was approved by the local institutional review board. Written informed consent was obtained from all patients before imaging. Twenty consecutive patients with myocardial infarction (n = 20) underwent cardiac PET/MR imaging examination. Ten patients underwent additional cardiac PET/computed tomography (CT) before PET/MR. Two-dimensional half-Fourier acquisition single-shot turbo spin-echo sequences, balanced steady-state free precession cine sequences, two-dimensional turbo inversion-recovery magnitude T2-weighted sequences, and late gadolinium-enhanced (LGE) segmented two-dimensional inversion-recovery turbo fast low-angle shot sequences were performed. According to the 17-segment model, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for each segment on a binary scale, and categorical intermethod agreement was calculated by using the Cohen κ. The maximum standardized uptake value was measured in corresponding myocardial locations on PET/CT and PET/MR images. RESULTS: Agreement was substantial over all patients and segments between PET and LGE images (κ = 0.76) and between PET and cine images (κ = 0.78). In 306 segments, 97 (32%) were rated as infarcted on PET images, compared with 93 (30%) rated as infarcted on LGE images and with 90 (29%) rated as infarcted on cine images. In a subgroup of patients (n = 10) with an additional PET/CT scan, no significant difference in myocardial tracer uptake between PET/CT and PET/MR images was found (paired t test, P = .95). CONCLUSION: Cardiac PET/MR imaging with FDG is feasible and may add complementary information in patients with ischemic heart disease.
PURPOSE: To assess the feasibility of hybrid imaging of the heart with fluorine 18 fluorodeoxyglucose (FDG) on an integrated 3-T positron emission tomography (PET)/magnetic resonance (MR) imaging system. MATERIALS AND METHODS: The present study was approved by the local institutional review board. Written informed consent was obtained from all patients before imaging. Twenty consecutive patients with myocardial infarction (n = 20) underwent cardiac PET/MR imaging examination. Ten patients underwent additional cardiac PET/computed tomography (CT) before PET/MR. Two-dimensional half-Fourier acquisition single-shot turbo spin-echo sequences, balanced steady-state free precession cine sequences, two-dimensional turbo inversion-recovery magnitude T2-weighted sequences, and late gadolinium-enhanced (LGE) segmented two-dimensional inversion-recovery turbo fast low-angle shot sequences were performed. According to the 17-segment model, PET tracer uptake, wall motion, and late gadolinium enhancement were visually assessed for each segment on a binary scale, and categorical intermethod agreement was calculated by using the Cohen κ. The maximum standardized uptake value was measured in corresponding myocardial locations on PET/CT and PET/MR images. RESULTS: Agreement was substantial over all patients and segments between PET and LGE images (κ = 0.76) and between PET and cine images (κ = 0.78). In 306 segments, 97 (32%) were rated as infarcted on PET images, compared with 93 (30%) rated as infarcted on LGE images and with 90 (29%) rated as infarcted on cine images. In a subgroup of patients (n = 10) with an additional PET/CT scan, no significant difference in myocardial tracer uptake between PET/CT and PET/MR images was found (paired t test, P = .95). CONCLUSION: Cardiac PET/MR imaging with FDG is feasible and may add complementary information in patients with ischemic heart disease.
Authors: D L Bailey; B J Pichler; B Gückel; H Barthel; A J Beer; J Bremerich; J Czernin; A Drzezga; C Franzius; V Goh; M Hartenbach; H Iida; A Kjaer; C la Fougère; C N Ladefoged; I Law; K Nikolaou; H H Quick; O Sabri; J Schäfer; M Schäfers; H F Wehrl; T Beyer Journal: Mol Imaging Biol Date: 2015-10 Impact factor: 3.488
Authors: Jorge D Oldan; Shetal N Shah; Richard C Brunken; Frank P DiFilippo; Nancy A Obuchowski; Michael A Bolen Journal: J Nucl Cardiol Date: 2015-06-13 Impact factor: 5.952
Authors: Felix Nensa; E Tezgah; K Schweins; J Goebel; P Heusch; K Nassenstein; T Schlosser; T D Poeppel Journal: J Nucl Cardiol Date: 2016-03-18 Impact factor: 5.952
Authors: Jeffrey M C Lau; R Laforest; H Sotoudeh; X Nie; S Sharma; J McConathy; E Novak; A Priatna; R J Gropler; P K Woodard Journal: J Nucl Cardiol Date: 2015-10-23 Impact factor: 5.952